Trends in the susceptibility of commonly encountered clinically significant anaerobes and susceptibilities of blood isolates of anaerobes to 16 antimicrobial agents, including fidaxomicin and rifaximin, 2008–2012, northern Taiwan

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 11, 2014, Pages 2041-2052

  Wang, F D ^a   Liao, C H ^b   Lin, Y T ^a   Sheng, W H ^c   Hsueh, P R ^c  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; CEFMETAZOLE; CEFOPERAZONE PLUS SULBACTAM; CHLORAMPHENICOL; CLINDAMYCIN; ERTAPENEM; FIDAXOMICIN; IMIPENEM; METRONIDAZOLE; MOXIFLOXACIN; RIFAXIMIN; SULTAMICILLIN; TIGECYCLINE; AMINOGLYCOSIDE; RIFAMYCIN;

ANAEROBE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTEROIDES; BACTEROIDES FRAGILIS; BACTEROIDES UNIFORMIS; CLOSTRIDIUM; CLOSTRIDIUM PERFRINGENS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARVIMONAS MICRA; PREVOTELLA; TAIWAN; TREND STUDY; ANAEROBIC BACTERIUM; BACTEREMIA; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; AMINOGLYCOSIDES; ANTI-INFECTIVE AGENTS; BACTEREMIA; BACTERIA, ANAEROBIC; DRUG RESISTANCE, BACTERIAL; EPIDEMIOLOGICAL MONITORING; HUMANS; MICROBIAL SENSITIVITY TESTS; RIFAMYCINS; TAIWAN;

EID: 84911007673     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2175-y     Document Type: Article

References (30)

1. Goldstein EJC, Citron DM (2011) Resistance trends in antimicrobial susceptibility of anaerobic bacteria, part I. Clin Microbiol Newsl 33:1–8
2. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rosenblatt J, Venezia R, Gorbach SL, Queenan AM, Hecht DW (2011) Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe 17:147–151
3. Cuchural GJ Jr, Tally FP, Jacobus NV, Aldridge K, Cleary T, Finegold SM, Hill G, Iannini P, O’Keefe JP, Pierson C. Crook D, Russo T, Hecht D (1988) Susceptibility of the Bacteroides fragilis group in the United States: analysis by site of isolation. Antimicrob Agents Chemother 32:717–722
4. Nagy E, Urbán E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria (2011) Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin Microbiol Infect 17:371–379
5. Nguyen MH, Yu VL, Morris AJ, McDermott L, Wagener MW, Harrell L, Snydman DR (2000) Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 30:870–876
6. Liu CY, Huang YT, Liao CH, Yen LC, Lin HY, Hsueh PR (2008) Increasing trends in antimicrobial resistance among clinically important anaerobes and Bacteroides fragilis isolates causing nosocomial infections: emerging resistance to carbapenems. Antimicrob Agents Chemother 52:3161–3168
7. Clinical and Laboratory Standards Institute (CLSI) (2007) Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A7, 7th edn. CLSI, Wayne
8. Clinical and Laboratory Standards Institute (CLSI) (2012) Methods for antimicrobial susceptibility testing of anaerobic bacteria. Approved standard M11-A8, 8th edn. CLSI, Wayne
9. U.S. Food and Drug Administration (FDA) (2007) Class II special controls guidance document: antimicrobial susceptibility test systems (AST); guidance for industry. U.S. Department of Health and Human Services, Food and Drug Administration, Washington, DC. Available online at: http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm080564.htm. Accessed 13 Feb 2013
10. Snydman DR, Jacobus NV, McDermott LA, Ruthazer R, Golan Y, Goldstein EJ, Finegold SM, Harrell LJ, Hecht DW, Jenkins SG, Pierson C, Venezia R, Yu V, Rihs J, Gorbach SL (2007) National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 51:1649–1655
11. Sóki J, Edwards R, Hedberg M, Fang H, Nagy E, Nord CE; ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria (2006) Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis strains from a European antibiotic susceptibility survey. Int J Antimicrob Agents 28:497–502
12. Ueno K, Kato N, Kato H (2002) The status of research on anaerobes in Japan. Clin Infect Dis 35(Suppl 1):S54–S57
13. Fernández-Canigia L, Litterio M, Legaria MC, Castello L, Predari SC, Di Martino A, Rossetti A, Rollet R, Carloni G, Bianchini H, Cejas D, Radice M, Gutkind G; Anaerobe Surveillance Team (2012) First national survey of antibiotic susceptibility of the Bacteroides fragilis group: emerging resistance to carbapenems in Argentina. Antimicrob Agents Chemother 56:1309–1314
14. Karlowsky JA, Walkty AJ, Adam HJ, Baxter MR, Hoban DJ, Zhanel GG (2012) Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010–2011: CANWARD surveillance study. Antimicrob Agents Chemother 56:1247–1252
15. Wexler HM, Molitoris D, St John S, Vu A, Read EK, Finegold SM. (2002) In vitro activities of faropenem against 579 strains of anaerobic bacteria. Antimicrob Agents Chemother 46:3669–3675
16. Infectious Diseases Society of Taiwan; Taiwan Surgical Society of Gastroenterology; Medical Foundation in Memory of Dr. Deh-Lin Cheng; Foundation of Professor Wei-Chuan Hsieh for Infectious Diseases Research and Education; CY Lee’s Research Foundation for Pediatric Infectious Diseases and Vaccines (2008) Guidelines for antimicrobial therapy of intra-abdominal infections in adults. J Microbiol Immunol Infect 41:279–281
17. Snydman DR, Jacobus NV, McDermott LA, Golan Y, Hecht DW, Goldstein EJ, Harrell L, Jenkins S, Newton D, Pierson C, Rihs JD, Yu VL, Venezia R, Finegold SM, Rosenblatt JE, Gorbach SL (2010) Lessons learned from the anaerobe survey: historical perspective and review of the most recent data (2005–2007). Clin Infect Dis 50(Suppl 1):S26–S33
18. Aldridge KE (2002) Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis 44:181–186
19. King A, Downes J, Nord CE, Phillips I; European Study Group (1999) Antimicrobial susceptibility of non-Bacteroides fragilis group anaerobic Gram-negative bacilli in Europe. Clin Microbiol Infect 5:404–416
20. Kuriyama T, Karasawa T, Nakagawa K, Nakamura S, Yamamoto E (2002) Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics. Oral Microbiol Immunol 17:285–289
21. Teng LJ, Hsueh PR, Tsai JC, Liaw SJ, Ho SW, Luh KT (2002) High incidence of cefoxitin and clindamycin resistance among anaerobes in Taiwan. Antimicrob Agents Chemother 46:2908–2913
22. Liao CH, Ko WC, Lu JJ, Hsueh PR (2012) Characterizations of clinical isolates of Clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan. Antimicrob Agents Chemother 56:3943–3949
23. Goldstein EJC, Babakhani F, Citron DM (2012) Antimicrobial activities of fidaxomicin. Clin Infect Dis 55(Suppl 2):S143–S148
24. Finegold SM, Molitoris D, Väisänen ML (2009) Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother 53:281–286
25. Koeth LM, Good CE, Appelbaum PC, Goldstein EJ, Rodloff AC, Claros M, Dubreuil LJ (2004) Surveillance of susceptibility patterns in 1297 European and US anaerobic and capnophilic isolates to co-amoxiclav and five other antimicrobial agents. J Antimicrob Chemother 53:1039–1044
26. Goldstein EJ, Citron DM, Warren YA, Tyrrell KL, Merriam CV, Fernandez HT (2006) In vitro activities of dalbavancin and 12 other agents against 329 aerobic and anaerobic gram-positive isolates recovered from diabetic foot infections. Antimicrob Agents Chemother 50:2875–2879
27. Wybo I, Piérard D, Verschraegen I, Reynders M, Vandoorslaer K, Claeys G, Delmée M, Glupczynski Y, Gordts B, Ieven M, Melin P, Struelens M, Verhaegen J, Lauwers S (2007) Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 59:132–139
28. Papaparaskevas J, Pantazatou A, Katsandri A, Legakis NJ, Avlamis A; Hellenic Study Group for Gram-Negative Anaerobic Bacteria (2005) Multicentre survey of the in-vitro activity of seven antimicrobial agents, including ertapenem, against recently isolated Gram-negative anaerobic bacteria in Greece. Clin Microbiol Infect 11:820–824
29. Lakhssassi N, Elhajoui N, Lodter JP, Pineill JL, Sixou M (2005) Antimicrobial susceptibility variation of 50 anaerobic periopathogens in aggressive periodontitis: an interindividual variability study. Oral Microbiol Immunol 20:244–252
30. Molina J, Barrantes G, Quesada-Gómez C, Rodríguez C, Rodríguez-Cavallini E (2014) Phenotypic and genotypic characterization of multidrug-resistant Bacteroides, Parabacteroides spp., and Pseudoflavonifractor from a Costa Rican Hospital. Microb Drug Resist [Epub ahead of print]